Tositumomab and Iodine I 131 Tositumomab

Hypersensitivity reactions, Anaphylaxis; Cyopenia

Hypersensitivity reactions, Anaphylaxis

• Medications for the treatment of such reactions should be available for immediate use.

Cytopenia

• The majority of patients who receive this therapeutic regimen experience severe thrombocytopneia and neutropenia. Do not administer this regimen to patients with > 25% lymphoma marrow involvement and/or impaired bone marrow reverse

Pregnancy Category X

Special Requirements

• This product contains a radioactive component and should be administered only by physicians and other health professionals qualified in training in the safe use and handling of radionuclides.
• Physicians must be in the process or have been certified by Corixa Corporation in dose calculation and administration of this product.

Patient Counseling Information

Bexxar

Package Inserts

Tositumomab

Additional Information

• PubMed - Tositumomab and Iodine I 131 Tositumomab